Drug Profile
HER 096
Alternative Names: CDNF; CDNF-protein; Cerebral dopamine neurotrophic factor - Herantis Pharma; HER-096; recombinant human CDNF; rhCDNFLatest Information Update: 07 Nov 2023
Price :
$50
*
At a glance
- Originator University of Helsinki
- Developer Herantis Pharma; Nanoform; Renishaw
- Class Antidementias; Antiparkinsonians; Nerve growth factors; Neuroprotectants; Recombinant proteins
- Mechanism of Action Neuron modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Alzheimer's disease; Parkinson's disease
Highest Development Phases
- Phase I/II Parkinson's disease
- No development reported Alzheimer's disease; Amyotrophic lateral sclerosis
Most Recent Events
- 29 Sep 2023 Herantis Pharma completes a phase-I trial in Parkinson's disease (In volunteers) in Finland (SC) (NCT05915247)
- 27 Apr 2022 Preclinical trials in Parkinson's disease in Finland (SC) (Herantis Pharma website, April 2022)
- 19 Apr 2022 First in human study of HER 096 is expected to commence in 2023 (SC) (Herantis Pharma website, April 2022)